MedPath

ALA fluorescence guided resections in malignant gliomas

Phase 1
Conditions
Health Condition 1: null- malignant gliomas
Registration Number
CTRI/2015/08/006122
Lead Sponsor
Intramural TMC
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Per-primum glioma

•Adults (18-65 years)

•Radiologically suspected malignant gliomas

•Variable contrast enhancement on MRI (patchy and/or non-uniform)

•Eligible for surgical therapy (craniotomy NOT stereotactic biopsy )

•No contraindication for surgery

Exclusion Criteria

•Poor general condition (KPS < 70)

•Prior treatment (except biopsy)

•Compromised renal/hepatic function.

•Immunocompromised status

•Known photosensitivity / allergy to 5-ALA

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1. Degree of fluorescence in different tumor regions. <br/ ><br>2. PPIX quantificationTimepoint: NA
Secondary Outcome Measures
NameTimeMethod
1. Proteomics differences in variably fluorescing regions.Timepoint: NA
© Copyright 2025. All Rights Reserved by MedPath